SEC Form 4 · accession 0001209191-18-029082
Allena Pharmaceuticals, Inc. · ALNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward Wholihan
Officer — Chief Financial Officer
Period of report
May 9, 2018
Accepted (ET)
May 10, 2018 · 11:27 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001624658
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 9, 2018 | M | 25,000 | $1.59 | A | 25,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.59 | May 9, 2018 | M | 25,000 | D | — | Sep 15, 2026 | Common Stock | 25,000 | 167,031 | D |
Explanation of responses
- F125% of the shares vested on June 20, 2017 and the remaining shares vest in 36 equal monthly installments thereafter